UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Statistical stability for multidimensional piecewise expanding maps

Proceedings of the American Mathematical Society, 2017-07, Vol.145 (7), p.3057-3068

2017

Volltextzugriff (PDF)

Prevalence and factors associated with unhealthy metabolic status according to body mass index: analysis of a national nutritional survey

Diabetology and metabolic syndrome, 2024-08, Vol.16 (1), p.1-10, Article 186

2024

Volltextzugriff (PDF)

Renormalization of two-dimensional piecewise linear maps: Abundance of 2-D strange attractors

Discrete and continuous dynamical systems. Series A, 2018-02, Vol.38 (2), p.941-966

2018

Volltextzugriff (PDF)

Persistent two-dimensional strange attractors for a two-parameter family of Expanding Baker Maps

Discrete and continuous dynamical systems. Series B, 2019-02, Vol.24 (2), p.657-670

2019

Volltextzugriff (PDF)

Renormalizable Expanding Baker Maps: Coexistence of strange attractors

Discrete and continuous dynamical systems. Series A, 2017-03, Vol.37 (3), p.1651-1678

2017

Volltextzugriff (PDF)

A phase 2/3 trial of oral azacitidine (Oral-AZA) in patients (pts) with low- or intermediate-risk myelodysplastic syndromes (MDS)

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.TPS7083-TPS7083

2023

Volltextzugriff (PDF)

How to Analytically Prove the Existence of Strange Attractors Using Measure Theory

Nonlinear Analysis and Boundary Value Problems, 2019, Vol.292, p.29-40

2019

Volltextzugriff (PDF)

Chaotic dynamics for two-dimensional tent maps

Nonlinearity, 2015-02, Vol.28 (2), p.407-434

2015

Volltextzugriff (PDF)

Younger Patients with Newly Diagnosed FLT3-Mutant AML Treated with Crenolanib Plus Chemotherapy Achieve Adequate Free Crenolanib Levels and Durable Remissions

Blood, 2019-11, Vol.134 (Supplement_1), p.1326-1326

2019

Volltextzugriff (PDF)

Expanding Baker Maps as models for the dynamics emerging from 3D-homoclinic bifurcations

Discrete and continuous dynamical systems. Series B, 2014-03, Vol.19 (2), p.523-541

2014

Volltextzugriff (PDF)

Efficacy of clofarabine and low-dose cytarabine combination for genetically high-risk acute myeloid leukemia prior to allogeneic stem cell transplantation

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.e18515-e18515

2017

Volltextzugriff (PDF)

Evaluation of Nine Forms of Metabolic Syndrome Diagnosis as Risk for Cardiovascular Disease: An Analysis of Isolated and Combined Metabolic Factors

Journal of endocrinology and metabolism, 2024-08, Vol.14 (4), p.194-206

2024

Volltextzugriff (PDF)

Analysis of anti-leukemic activity, predictive biomarker candidates, immune activation and pharmakodynamics in R/R AML and MDS in response to treatment with bemcentinib (BGB324), a first-in class selective AXL inhibitor, in a phase II open-label, multi-centre study

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.7020-7020

2018

Volltextzugriff (PDF)

The immunomodulatory activity of bemcentinib (BGB324): A first-in-class selective oral AXL inhibitor in patients with relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome

Journal of clinical oncology, 2018-02, Vol.36 (5_suppl), p.70-70

2018

Volltextzugriff (PDF)

First-in class selective AXL inhibitor bemcentinib (BGB324) in combination with LDAC or decitabine exerts anti-leukaemic activity in AML patients unfit for intensive chemotherapy: Phase II open-label study

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.7043-7043

2019

Volltextzugriff (PDF)

A biomarker-directed phase 2 trial of SY-1425, a selective retinoic acid receptor alpha agonist, in adult patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.TPS7071-TPS7071

2017

Volltextzugriff (PDF)

Hypomethylating Agents and Low-Dose Venetoclax for Relapse Acute Myeloid Leukemia after Allogeneic Stem Cell Transplantation

Biology of blood and marrow transplantation, 2020-03, Vol.26 (3), p.S104-S104

2020

Volltextzugriff (PDF)

Comparison of two major intergroup induction intensive regimens in Hispanic adolescent and young adults (AYA) with acute lymphocytic leukemia (ALL): The importance of a complete molecular response

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.7072-7072

2013

Volltextzugriff (PDF)

Breast cancer incidence in a large cohort of Peruvian women affiliated to a pre-paid system

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.e12570-e12570

2013

Volltextzugriff (PDF)

A phase II study of clofarabine and daunorubicin in patients age 60 or older with newly diagnosed adult acute myeloid leukemia

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.6602-6602

2012

Volltextzugriff (PDF)

Tratamiento de la norma societaria desde la perspectiva económica Hard Law vs Soft Law

Lumen, 2019-07, Vol.1 (15), p.128-135

Vigil Oliveros, Enrique

2019

Volltextzugriff (PDF)

1 – 25 von 61

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(43)
Mit Volltextzugriff
(40)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Statistical stability for multidimensional piecewise expanding maps

Prevalence and factors associated with unhealthy metabolic status according to body mass index: analysis of a national nutritional survey

Renormalization of two-dimensional piecewise linear maps: Abundance of 2-D strange attractors

Persistent two-dimensional strange attractors for a two-parameter family of Expanding Baker Maps

Renormalizable Expanding Baker Maps: Coexistence of strange attractors

A phase 2/3 trial of oral azacitidine (Oral-AZA) in patients (pts) with low- or intermediate-risk myelodysplastic syndromes (MDS)

How to Analytically Prove the Existence of Strange Attractors Using Measure Theory

Chaotic dynamics for two-dimensional tent maps

Younger Patients with Newly Diagnosed FLT3-Mutant AML Treated with Crenolanib Plus Chemotherapy Achieve Adequate Free Crenolanib Levels and Durable Remissions

Expanding Baker Maps as models for the dynamics emerging from 3D-homoclinic bifurcations

Efficacy of clofarabine and low-dose cytarabine combination for genetically high-risk acute myeloid leukemia prior to allogeneic stem cell transplantation

SY-1425, a Potent and Selective RARα Agonist, in Combination with Azacitidine Demonstrates a High Complete Response Rate and a Rapid Onset of Response in RARA-Positive Newly Diagnosed Unfit Acute Myeloid Leukemia

The Combination of AXL Inhibitor Bemcentinib and Low Dose Cytarabine Is Well Tolerated and Efficacious in Elderly Relapsed AML Patients: Update from the Ongoing BGBC003 Phase II Trial (NCT02488408)

Evaluation of Nine Forms of Metabolic Syndrome Diagnosis as Risk for Cardiovascular Disease: An Analysis of Isolated and Combined Metabolic Factors

Durable Responses Observed in Elderly AML Patients Unfit for Intensive Chemotherapy with First-in Class Selective AXL Inhibitor Bemcentinib (BGB324) in Combination with LDAC: Phase II Open-Label Study

Analysis of anti-leukemic activity, predictive biomarker candidates, immune activation and pharmakodynamics in R/R AML and MDS in response to treatment with bemcentinib (BGB324), a first-in class selective AXL inhibitor, in a phase II open-label, multi-centre study

The immunomodulatory activity of bemcentinib (BGB324): A first-in-class selective oral AXL inhibitor in patients with relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome

First-in class selective AXL inhibitor bemcentinib (BGB324) in combination with LDAC or decitabine exerts anti-leukaemic activity in AML patients unfit for intensive chemotherapy: Phase II open-label study

A biomarker-directed phase 2 trial of SY-1425, a selective retinoic acid receptor alpha agonist, in adult patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)

Early Results from a Biomarker-Directed Phase 2 Trial of Sy-1425 in Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Demonstrate DHRS3 Induction and Myeloid Differentiation Following Sy-1425 Treatment

Hypomethylating Agents and Low-Dose Venetoclax for Relapse Acute Myeloid Leukemia after Allogeneic Stem Cell Transplantation

Comparison of two major intergroup induction intensive regimens in Hispanic adolescent and young adults (AYA) with acute lymphocytic leukemia (ALL): The importance of a complete molecular response

Breast cancer incidence in a large cohort of Peruvian women affiliated to a pre-paid system

A phase II study of clofarabine and daunorubicin in patients age 60 or older with newly diagnosed adult acute myeloid leukemia

Tratamiento de la norma societaria desde la perspectiva económica Hard Law vs Soft Law

Suchergebnisse filtern